Does a Real Anti-Aging
Pill Already Exist?
One afternoon in the early 1980s, Suren Sehgal brought a strange package home from work and stashed it in his family’s freezer. Wedged beside the ice cream, it was wrapped in heavy plastic and marked, “DON’T EAT!” Inside were several small glass vials containing a white paste—all that remained of a rare bacterium that today is the foundation of the most promising anti-aging drug in decades. Sehgal had been studying it since 1972, when he’d first isolated it in a soil sample at Ayerst Laboratories, a pharmaceutical company in Montreal.
A Canadian medical expedition had collected the soil from beneath one of the mysterious stone heads on Easter Island, a speck in the middle of the Pacific Ocean. In the dirt, Sehgal had discovered Streptomyces hygroscopicus, a bacterium that secreted a potent antifungal compound. This intrigued him; he thought perhaps it could be made into a cream for athlete’s foot or other fungal conditions. He purified the stuff and named it rapamycin, after Easter Island’s native name, Rapa Nui.
It soon proved its potential. When a neighbor’s wife developed a stubborn fungal skin condition, Sehgal mixed up a rapamycin ointment for her. “It was probably illegal,” says his son Ajai Sehgal, but the infection cleared up quickly. Suren, a biochemist who’d immigrated to Canada from a tiny village in what’s now Pakistan, became convinced that he’d stumbled upon something special. Before he could develop it any further, however, Ayerst abruptly closed its Montreal lab, and his bosses ordered all “nonviable” compounds destroyed—including the rapamycin. Sehgal couldn’t bring himself to do it and instead squirreled a few vials of Streptomyces hygroscopicus into his freezer at home. Most of the staff was fired, but Sehgal was transferred to the company’s lab in Princeton, N.J. The plastic package made the move packed in dry ice.
https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-
When general population discuss today’s medicine, accuracy plays one of the most significant roles and human lives are directly dependent on it. Likewise, any researches related to medicine are necessary to meet the highest standards. The issue today is that any outcomes of researches can be posted online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and attempted to come up with an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been established back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality measure. That assists both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website demonstrates a full publications list with respective scores higher than 100 as well as reports discussed above. Mikhail (Misha) Blagosklonny proud to share his new approach and hopes it creates the required assistance to anybody, who has interest in oncology.
https://sketchfab.com/blagosklonny9
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This article was published back in 2018 by Oncotarget and written by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and shares an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that most of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Likewise, the article about melanoma, was used for citations in various news articles 69 times. Besides that, it was quoted in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their news on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s study with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This study has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive useful scientific facts. Oncotarget is proud to have the chance to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
https://scholar.google.com/scholar?q=Blagosklonny&hl=en&as_sdt=0&as_vis=1&oi=scholart
Comments
Post a Comment